Cargando…
Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study
Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has shown antitumor activity against different cancer types, including non-small cell lung cancer (NSCLC). In this work, w...
Autores principales: | Sabet, Ziba, Vagiannis, Dimitrios, Budagaga, Youssif, Zhang, Yu, Novotná, Eva, Hanke, Ivo, Rozkoš, Tomáš, Hofman, Jakub |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697930/ https://www.ncbi.nlm.nih.gov/pubmed/36430819 http://dx.doi.org/10.3390/ijms232214338 |
Ejemplares similares
-
Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo
por: Zhang, Yu, et al.
Publicado: (2022) -
Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
por: Vagiannis, Dimitrios, et al.
Publicado: (2021) -
Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme
por: Vagiannis, Dimitrios, et al.
Publicado: (2020) -
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo
por: Hill, Christopher R., et al.
Publicado: (2013) -
Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
por: Talebi, Zahra, et al.
Publicado: (2023)